ReShape Lifesciences Presents Data on its Proprietary Diabetes BlocStim Neuromodulation Device at the ASMBS 2023 Annual Meeting

IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromodulation (DBSN) device in an e-poster at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Meeting,…Read More

Leave a Reply

Your email address will not be published. Required fields are marked *